Skip to main content
OpenTrials
Completed

NCT Number: NCT01795326

Physician Survey on Monitoring of Patients Treated With Quetiapine

A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Bipolar Disorder Bipolar and Related Disorders Depressive Disorder Depressive Disorder, Major Major Depressive Disorder Mental Disorders Mood Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Sex eligibility

All sexes

Study type

Observational

About this study

Assessment of physician behavior regarding metabolic monitoring of patients treated with SEROQUEL® (quetiapine fumarate) Tablets and SEROQUEL® (quetiapine fumarate) Extended Release Tablets in selected countries in the EU

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Physicians targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.

Exclusion criteria

  • Physicians who have participated in a survey involving SEROQUEL® / SEROQUEL® XR in the past six months are not eligible to participate in this survey.

Treatment and study plan

Primary outcomes

  1. Determination via survey whether physicians or someone in their practice perform monitoring of patients treated with Seroquel or Seroquel XR for metabolic issues related to treatment; refer their patients to another physician for monitoring.

    Time frame: Over 6- 8 weeks.

  2. Determination via survey whether physicians monitor tests for hyperlipidemia in patients who are taking Seroquel or Seroquel XR.

    Time frame: Over 6- 8 weeks.

  3. Determination via survey whether physicians monitor for signs and symptoms of hyperglycemia in patients who are taking Seroquel or Seroquel XR.

    Time frame: Over 6- 8 weeks.

  4. Determination via survey whether physicians monitor blood glucose in patients with diabetes or monitor patients with risk factors for diabetes for worsening of glycemic control if they are taking Seroquel or Seroquel XR.

    Time frame: Over 6- 8 weeks.

  5. Determination via survey whether physicians monitor weight at initiation of treatment with Seroquel or Seoquel XR and on a regular basis after initiating treatment.

    Time frame: Over 6- 8 weeks.

Secondary outcomes

  1. Determination via survey whether physicians counsel patients taking with Seroquel or Seroquel XR on healthy eating, exercise, and healthy lifestyle improvements.

    Time frame: Over 6- 8 weeks.

  2. Determination via survey whether physicians received educational information relevant to the issues in the survey from AstraZeneca.

    Time frame: Over 6- 8 weeks.

  3. Determination via survey whether physicians read the educational information.

    Time frame: Over 6- 8 weeks.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Assessment of Physician Behavior Regarding Metabolic Monitoring of Patients Treated With SEROQUEL® (Quetiapine Fumarate) Tablets and SEROQUEL® (Quetiapine Fumarate) Extended Release Tablets in Selected Countries in the EU

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Feb 20, 2013
Registry last updated
Jan 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.